Optimizing Heart Failure Outcomes with Intravenous Iron: Adaptive Approaches for Effective Diagnosis and Treatment of Iron Deficiency in HFrEF

Target audience is Cardiologists and key members of their interprofessional and multidisciplinary care teams who manage patients with heart failure.

At the conclusion of this activity, participants will be able to:
Summarize the basic principles of iron metabolism and absorption, with a focus on how these principles apply to treatment of iron deficiency (ID) in heart failure (HF), distinguishing between HFrEF and HFpEF in terms of presentation and treatment standards.

Review the pivotal role of hepcidin in ID pathophysiology, especially in a hyperinflammatory condition like HF, and recognize the prognostic impact of ID, irrespective of concomitant anemia, on patient functional capacity, quality of life, and HF morbidity and mortality endpoints.

Evaluate the fundamental utility of serum ferritin and transferrin saturation (TSAT) as laboratory indices for ID diagnosis, and differentiate the practical distinctions between functional and absolute ID in the setting of HF.

Appraise completed, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and dis-cuss recent pivotal data readouts that have influenced current practice and informed consensus HF guideline statements (2021 ESC and 2022 ACC/AHA/HFSA).

Compare and contrast FDA-approved IV iron agents, including updated label indications and dosing regimens, and understand how the nanoparticle design of next-generation IV iron products has dramatically improved safety profiles vs. older agents.

Using a case-based format, analyze how inflammation impacts the comparative clinical utility of oral iron vs. IV iron in HF, and design real-world treatment strategies with IV iron that promote HF GDMT, incorporate novel tools, and optimize outcomes

Javed Butler, MD, MPH, MBA (Activity Chair)
President, Baylor Scott and White Research Institute, Patrick H. Lehan Chair in Cardiovascular Research, Professor and Chairman, Department of Medicine, University of Mississippi Medical Center, Jackson, MS

Stefan D. Anker, MD, PhD
Professor of Cardiology and Cachexia Research, Department of Cardiology, Charite University, Berlin, Germany

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine, Director, Winters Center for Heart Failure Research, Associate Director, Cardiovascular Research Institute, Vice-Chair of Medicine, Baylor College of Medicine, Medicine Chief, DeBakey VA Medical Center, Houston, TX

Muthiah Vaduganathan, MD, MPH, Co-Director, Center for Cardiometabolic Implementation Science, Harvard Medical School, Brigham and Women's Hospital Cardiovascular Medicine, Boston, MA

Welcome and Introductions
Javed Butler, MD, MPH, MBA

Heart Failure Disease State Review: The Pathophysiology and Clinical Gravity of Concomitant Iron Deficiency
Javed Butler, MD, MPH, MBA

A New Standard in Heart Failure Management: Ushering in the Era of Intravenous Iron as a Pillar of Care
Stefan D. Anker, MD, PhD
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP

Cardiology Catalysts: Real-world Strategies for Closing the Iron Deficiency Chasm in HFrEF
Muthiah Vaduganathan, MD, MPH with interactive panel discussion

Q&A/Panel Discussion
All faculty, moderated by Javed Butler, MD, MPH, MBA

Supported through an independent educational grant from American Regent.

Physicians
The Heart Failure Society of America designates this educational activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extend of their participation in the activity.

Nurses
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum 1.5 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.